1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd

3,621.45
INR
+188.40
(+5.49%)
78.09EPS
35.87P/E
29.06BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
57.43
50.48
74.05
191.3
132.23
160.3
134.25
252.57
439.65
241.93
295.94
356.78
484.82
533.76
Basic EPS, GAAP
0.9
0.88
1.55
6.55
4.38
7.28
8.02
14.6
115.64
18.67
22.93
38.4
64.9
78.1
Free Cash Flow per Basic Share
-3.87
-0.34
-5.42
-4.86
-6.68
1.69
-14.08
3.19
5.25
-6.06
12.67
26.71
-31.18
- -
Dividend per Share
- -
- -
- -
0.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
17.75
19.19
21.72
24.66
28.67
35.95
44.34
58.94
174.58
193.25
216.08
254.48
319.57
- -
Tangible Book Value per Share
17.75
19.19
21.72
24.66
28.67
35.95
44.34
58.94
174.58
193.25
216.08
252.83
313.94
- -
Basic Weighted Avg Shares
10
10
10
5
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
596
524
742
983
1,372
1,663
1,393
2,620
4,562
2,510
3,071
3,702
5,031
5,540
Operating Margin (%)
3.91
4.35
5.38
7.94
6.37
7.57
8.45
8.65
35.29
18.23
15.24
16.77
19.57
20.77
Depreciation Expense
12
13
17
25
30
31
44
65
107
150
196
183
198
200
Net Income, GAAP
9
9
16
34
45
76
83
151
1,200
194
238
398
673
811
Effective Tax Rate (%)
46.47
40.52
48.22
41.95
39.4
30.74
24.83
30.01
25.77
24.61
24.06
26.48
24.75
23.86
Profit Margin (%)
1.57
1.75
2.09
3.42
3.31
4.54
5.97
5.78
26.3
7.72
7.75
10.76
13.39
14.63
Working Capital
71
70
116
115
130
145
213
276
883
813
908
1,143
1,802
- -
LT Debt
14
8
27
33
47
76
102
183
203
273
196
151
296
- -
Total Equity
178
191
213
251
288
363
450
599
1,798
1,991
2,226
2,624
3,299
- -
Return on Invested Capital (%)
- -
5.47
6.14
11.22
10.18
13.83
11.8
16.69
62.62
7.74
9.58
12.78
17.26
- -
Return on Capital (%)
- -
6.51
7.99
11.58
12.08
15.18
14.22
19.09
72.99
9.18
10.45
13.56
18.1
- -
Return on Common Equity (%)
- -
4.95
7.59
14.21
16.43
22.53
19.97
28.27
99.05
10.15
11.21
16.32
22.61
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,011
- -
LT Borrowings
- -
294
- -
LT Finance Leases
- -
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
11,500
13,555
29,065

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
4,057
- -
Cash, Cash Equivalents & STI
- -
36
- -
Accounts Receivable, Net
- -
2,801
- -
Inventories
- -
783
- -
Total Current Liabilities
- -
2,255
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,011
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.19%
53.31%
25.73%
Free Cash Flow
-162.25%
-113.12%
-216.74%
Net Income, GAAP
107.77%
153.54%
69.02%
Sales/Revenue/Turnover
27.31%
21.58%
35.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
801
900
844
1,157
3,702
2026
1,115
1,111
1,234
1,571
5,031
2027
1,624
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
8.04
8.15
8.21
13.95
38.4
2026
11.49
13.6
15.42
24.39
64.9
2027
24.69
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ramesh Arora
Full Time Employees
1,137
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Village Nagkalan Amritsar PU India 143601
IPO Date
Jul 18, 2016
Website
kwalitypharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kwality Pharmaceuticals Limited manufactures and exports finished pharmaceutical formulations across diverse dosage forms including tablets, capsules, liquid orals, sterile powders for injection, ointments, ophthalmic suspensions, liquid injections, dry powders for oral suspension, lyophilized injections, vials, ampoules, eye/ear/nasal drops, creams, gels, suppositories, pre-filled syringes, bolus, and external preparations; the company specializes in complex generics, niche injectables, cephalosporins, beta-lactams, oncology products, and biologics such as Kwai Poietin, covering over 25 therapeutic areas like critical care, anaesthesia, cardiac, pain management, systemic anti-infectives, cytotoxic and allied products, sex hormones, and synthetic hormones, while also dealing in drug intermediates, chemicals, extracts, alkaloids, and other medical preparations. Headquartered in Amritsar, Punjab, India, with additional manufacturing facilities in Jassur, Himachal Pradesh, Kwality Pharmaceuticals operates from multiple specialized units including general, beta-lactam, cephalosporin, oncology, and biologics facilities, exporting to regulated and semi-regulated markets across Europe, Latin America, Africa, MENA, GCC, Russia, Asia, and CIS regions. Founded in 1983, the company holds prestigious certifications such as EU-GMP for four units (general, beta-lactam, cephalosporin, oncology), PIC/s GMP from Brazil, ANVISA, SFDA, WHO-GMP, INVIMA, COFEPRIS, and DIGEMID. Recent developments include successful EU-GMP audits for general and beta-lactam units at Amritsar in 2025, approval and commercialization of Leuprorelin Acetate 11.25 mg in Greece via a strategic CDMO partnership expected to generate USD 3 million in annual revenue starting January 2025, establishment of a biologics unit in 2023 with promising results for its first biologic Kwai Poietin, PIC/s approval for the beta-lactam unit, SFDA PIC/s approval for the general injectable unit, and DSIR approval for its Innovation Center R&D facility.